Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers
Primary Purpose
Diabetic Foot Ulcers
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Regranex®
Hydrogel
Sponsored by
About this trial
This is an interventional treatment trial for Diabetic Foot Ulcers focused on measuring diabetes mellitus, diabetic neuropathies, peripheral vascular diseases
Eligibility Criteria
Inclusion Criteria:
- Subject must sign an informed consent
- Have a history of compliance and reliability in following study required treatment regimen.
- Have diabetic mellitus Type I or Type II and have a glycohemoglobin Alc less than l0
Presence of one or two ulcers in lower extremities
- Wounds cannot be positioned more than 2.5cm proximal to the malleoli, but may involve any more distal position of the foot
- Type 2 Diabetic Mellitus Neuropathic ulcers present at least for 3months with failure to heal
- Post-operation wounds in DM patients with wound present for minimum 4 weeks after surgery and wound surface area has failed to decrease more than 20% in 4 weeks
- Ulcer(s) must be stage II or III full-thickness (extending through the subcutaneous tissue or beyond - Wagner grade II or III)
- No joint, tendon or bone exposure
- Located on the lower extremity.
- Ulcer size measures 1cm2 < 16 cm2
- No osteomyelitis affecting the area of the ulcer
- If two wounds, both can be incorporated into one window when cast applied
- Adequate foot arterial circulation evidenced by palpable ankle pulses or Doppler with ABI less than or equal to 0.8. If non-compressible, must have triphasic wave Doppler velocity waveforms or toe/brachial pressure greater than or equal to 0.6.
Exclusion criteria:
- Female subjects who are within child bearing age range.
- Previous sensitivity to Regranex® Gel.
- Use of topical antibiotics, enzymatic debriders on the selected ulcer(s) within 30 days preceding randomization.
- Osteomyelitis affecting the area of the selected ulcer(s)
- Exposed bone, joint or tendon at ulcer site (Wagner III or higher)
- Presence of more than two full-thickness ulcers on targeted lower extremity
- Requirement for systemic antibiotics use within 7 days of study entry
- Inability to tolerate cast
- Presence of systemic or local cancer of any kind
- Life expectancy less than 1 year
- Subjects with end stage renal failure requiring chronic hemodialysis
- Concomitant use of Pletal or other vasodilators
- Ankle Brachial Index less or equal to 0.8 or toe pressure index less than 0.6
- ESR>20
- Demonstration of poor compliance including a chronic alcohol, psychiatric condition or drug abuse problems
Sites / Locations
- VA Long Beach Healthcare SystemRecruiting
- VA Greater Los Angeles Healthcare SystemRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Randomized to Regranex gel
Placebo hydrogel will be used for a total of 16 weeks
Outcomes
Primary Outcome Measures
Completely healed wounds
Secondary Outcome Measures
Full Information
NCT ID
NCT00446472
First Posted
March 8, 2007
Last Updated
June 2, 2010
Sponsor
Southern California Institute for Research and Education
Collaborators
Heritage Medical Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT00446472
Brief Title
Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers
Official Title
Evaluation of Windowed Casts With and Without Regranex® Gel for Healing
Study Type
Interventional
2. Study Status
Record Verification Date
June 2010
Overall Recruitment Status
Unknown status
Study Start Date
April 2007 (undefined)
Primary Completion Date
September 2010 (Anticipated)
Study Completion Date
September 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Southern California Institute for Research and Education
Collaborators
Heritage Medical Research Institute
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study is to compare the effectiveness and safety of windowed casts with Regranex® (topical becaplermin gel) versus placebo (inactive medication) for treatment of diabetic ulcers on the legs and feet.
Detailed Description
Management of diabetic leg or foot ulcers is based on certain principals: 1) effective off-loading of pressure on the wound via specialized shoes, cast braces, or casts, 2) removal of infected or necrotic tissue vial surgery or non-surgical methods, and 3) optimization of wound healing by interventions that promote wound repair such as nutritional support, provision of optimal moisture balance and growth factor therapy.
Application of casts or cast braces [below knee, removable boots with protective padding] to protect and immobilize the ankle and foot have been demonstrated to provide superior wound healing than less cumbersome types of shoe gear (1-3). The benefit of casting may be the result of more effective off-loading of pressure than can be achieved with other devices, but the inability of patients to remove their casts also appears to an important factor, as non-compliance with removable cast-braces has been shown to be a pervasive and significant issue (4,5). One critical concept in diabetic foot ulcer management is the relation between chronically and limb loss - for each year a wound persists, a patient has a 25% risk for major amputation due to complications from infection (6-8). Limb loss has a profound effect on Diabetics' quality of life and rate of lower limb loss among diabetics is four per 1,000 person years in comparison with three per 10,000 person years (9-10).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Foot Ulcers
Keywords
diabetes mellitus, diabetic neuropathies, peripheral vascular diseases
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Randomized to Regranex gel
Arm Title
2
Arm Type
Active Comparator
Arm Description
Placebo hydrogel will be used for a total of 16 weeks
Intervention Type
Drug
Intervention Name(s)
Regranex®
Other Intervention Name(s)
Becaplermin
Intervention Description
Regranex gel will be used for a total of 16 weeks
Intervention Type
Drug
Intervention Name(s)
Hydrogel
Intervention Description
Placebo hydrogel will be applied for 16 weeks
Primary Outcome Measure Information:
Title
Completely healed wounds
Time Frame
4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject must sign an informed consent
Have a history of compliance and reliability in following study required treatment regimen.
Have diabetic mellitus Type I or Type II and have a glycohemoglobin Alc less than l0
Presence of one or two ulcers in lower extremities
Wounds cannot be positioned more than 2.5cm proximal to the malleoli, but may involve any more distal position of the foot
Type 2 Diabetic Mellitus Neuropathic ulcers present at least for 3months with failure to heal
Post-operation wounds in DM patients with wound present for minimum 4 weeks after surgery and wound surface area has failed to decrease more than 20% in 4 weeks
Ulcer(s) must be stage II or III full-thickness (extending through the subcutaneous tissue or beyond - Wagner grade II or III)
No joint, tendon or bone exposure
Located on the lower extremity.
Ulcer size measures 1cm2 < 16 cm2
No osteomyelitis affecting the area of the ulcer
If two wounds, both can be incorporated into one window when cast applied
Adequate foot arterial circulation evidenced by palpable ankle pulses or Doppler with ABI less than or equal to 0.8. If non-compressible, must have triphasic wave Doppler velocity waveforms or toe/brachial pressure greater than or equal to 0.6.
Exclusion criteria:
Female subjects who are within child bearing age range.
Previous sensitivity to Regranex® Gel.
Use of topical antibiotics, enzymatic debriders on the selected ulcer(s) within 30 days preceding randomization.
Osteomyelitis affecting the area of the selected ulcer(s)
Exposed bone, joint or tendon at ulcer site (Wagner III or higher)
Presence of more than two full-thickness ulcers on targeted lower extremity
Requirement for systemic antibiotics use within 7 days of study entry
Inability to tolerate cast
Presence of systemic or local cancer of any kind
Life expectancy less than 1 year
Subjects with end stage renal failure requiring chronic hemodialysis
Concomitant use of Pletal or other vasodilators
Ankle Brachial Index less or equal to 0.8 or toe pressure index less than 0.6
ESR>20
Demonstration of poor compliance including a chronic alcohol, psychiatric condition or drug abuse problems
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ian Gordon, M.D., Ph.D.
Organizational Affiliation
VA Long Beach Healthcare System
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Aksone Nouvong, D.P.M.
Organizational Affiliation
VA Greater Los Angeles Healthcare System
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Long Beach Healthcare System
City
Long Beach
State/Province
California
ZIP/Postal Code
90822
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christine Ma Agas
Phone
562-826-8000
Ext
2889
Email
christine.ma@va.gov
First Name & Middle Initial & Last Name & Degree
Ian Gordon, M.D., Ph.D.
Facility Name
VA Greater Los Angeles Healthcare System
City
Los Angeles
State/Province
California
ZIP/Postal Code
90073
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aksone Nouvong, D.P.M.
Phone
310-268-3193
Email
aksone.nouvong@va.gov
First Name & Middle Initial & Last Name & Degree
Aksone Nouvong, D.P.M.
12. IPD Sharing Statement
Citations:
PubMed Identifier
11375363
Citation
Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care. 2001 Jun;24(6):1019-22. doi: 10.2337/diacare.24.6.1019. Erratum In: Diabetes Care 2001 Aug;24(8):1509.
Results Reference
background
PubMed Identifier
14514590
Citation
Ha Van G, Siney H, Hartmann-Heurtier A, Jacqueminet S, Greau F, Grimaldi A. Nonremovable, windowed, fiberglass cast boot in the treatment of diabetic plantar ulcers: efficacy, safety, and compliance. Diabetes Care. 2003 Oct;26(10):2848-52. doi: 10.2337/diacare.26.10.2848.
Results Reference
background
PubMed Identifier
11128345
Citation
Caravaggi C, Faglia E, De Giglio R, Mantero M, Quarantiello A, Sommariva E, Gino M, Pritelli C, Morabito A. Effectiveness and safety of a nonremovable fiberglass off-bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers: a randomized study. Diabetes Care. 2000 Dec;23(12):1746-51. doi: 10.2337/diacare.23.12.1746.
Results Reference
background
PubMed Identifier
12941724
Citation
Armstrong DG, Lavery LA, Kimbriel HR, Nixon BP, Boulton AJ. Activity patterns of patients with diabetic foot ulceration: patients with active ulceration may not adhere to a standard pressure off-loading regimen. Diabetes Care. 2003 Sep;26(9):2595-7. doi: 10.2337/diacare.26.9.2595.
Results Reference
background
PubMed Identifier
15735186
Citation
Armstrong DG, Lavery LA, Wu S, Boulton AJ. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. Diabetes Care. 2005 Mar;28(3):551-4. doi: 10.2337/diacare.28.3.551.
Results Reference
background
PubMed Identifier
8542736
Citation
Larsson J, Apelqvist J, Agardh CD, Stenstrom A. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? Diabet Med. 1995 Sep;12(9):770-6. doi: 10.1111/j.1464-5491.1995.tb02078.x.
Results Reference
background
PubMed Identifier
1936593
Citation
Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes. 1991 Oct;40(10):1305-13. doi: 10.2337/diab.40.10.1305.
Results Reference
background
PubMed Identifier
9602314
Citation
Bergink GJ, Hoyng CB, van der Maazen RW, Vingerling JR, van Daal WA, Deutman AF. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefes Arch Clin Exp Ophthalmol. 1998 May;236(5):321-5. doi: 10.1007/s004170050085.
Results Reference
background
Citation
U.S. Department of Health and Human Services. Healthy People 2010: Understanding and improving health, vol.2. Washington, DC: US Government Printing Office, 2000
Results Reference
background
PubMed Identifier
2351029
Citation
Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care. 1990 May;13(5):513-21. doi: 10.2337/diacare.13.5.513.
Results Reference
background
Links:
URL
http://www.scire-lb.org
Description
Southern California Institute for Research and Education (SCIRE) Website
Learn more about this trial
Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers
We'll reach out to this number within 24 hrs